Location History:
- Ibaraki, JP (2010 - 2012)
- Wako, JP (2015 - 2022)
Company Filing History:
4 out of 856 
1 out of 8 
1 out of 1,035 
Years Active: 2010-2022
Title: Soichi Kojima: Innovator in Biopharmaceuticals
Introduction
Soichi Kojima is a notable inventor based in Wako, Japan, who has made significant contributions to the field of biopharmaceuticals. With a total of four patents to his name, Kojima's research focuses on innovative solutions related to human health and disease treatment. His work has far-reaching implications, particularly in the context of viral infections and immune response modulation.
Latest Patents
Kojima's latest patents demonstrate his expertise in developing monoclonal antibodies and compounds targeting specific mechanisms of disease. One of his key patents is for an antibody against human TGF-β LAP (Latency Associated Protein) degradate. This isolated monoclonal antibody is designed to recognize an integrin binding site in the human TGF-β LAP degradate, providing a potential therapeutic avenue for diseases mediated by TGF-β signaling.
Another significant patent focuses on compounds intended to suppress the activation of TGF-β receptors, particularly in the context of hepatitis C virus (HCV) infection. This patent outlines a method for screening such compounds, revealing how the HCV-derived NS3 protease interacts with type I TGF-β receptor and subsequently activates it. Kojima's findings about the binding sites between the NS3 protease and the receptor offer crucial insights that could lead to innovative treatments for conditions exacerbated by HCV.
Career Highlights
Throughout his career, Soichi Kojima has worked with prestigious institutions, including RIKEN Corporation and The Jikei University, where he has further honed his research skills and expertise. His contributions extend beyond his patents, as he continues to influence the field through impactful research in biomedicine.
Collaborations
Kojima's work is also underscored by valuable collaborations. He has notably worked alongside fellow researchers Naoshi Dohmae and Wakako Kondo, contributing to the progress in understanding molecular interactions and therapeutic applications. Collaborative efforts like these highlight the importance of teamwork in advancing scientific knowledge and innovation.
Conclusion
Soichi Kojima's inventive contributions in the realm of biopharmaceuticals showcase the significance of targeted therapeutic strategies in modern medicine. With his ongoing research and innovation, Kojima is poised to make a lasting impact on the treatment of viral infections and the modulation of immune responses, thereby enhancing the landscape of healthcare solutions.